The following is a summary of “CD1a affects the recurrence and prognosis of ovarian cancer,” published in the November 2024 ...
Medpage Today on MSN9d
Adding HIPEC Boosts Survival in Recurrent Ovarian CancerThe 5-year OS rates were 46% in the HIPEC group versus 38% in the no-HIPEC group, they noted in Lancet Oncology. The trial ...
The following is a summary of “Hyperthermic Intraperitoneal Chemotherapy in Platinum-Sensitive Recurrent Ovarian Cancer: A ...
Ovarian cancer vaccines are under development, but none are ready for primetime. There are no screening tools for ovarian ...
It induces a specific type of immunity, called Th17 immunity, that seems to prevent suppression of the immune system. The ...
Anixa Biosciences begins patient dosing in third cohort in ongoing phase 1 trial of novel CAR-T therapy for recurrent ovarian cancer: San Jose, California Wednesday, November 20, ...
Anixa Biosciences, Inc. (NASDAQ: ANIX) shares nosed up Monday, as the biotechnology company focused on the <a target=_blank ...
Mass spectrometry and machine learning show promise for early cancer detection and prognosis by analyzing metabolic ...
A molar pregnancy, also known as a hydatidiform mole, is an abnormal human pregnancy with no embryo and an overgrowth of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback